# Shanghai Junshi Biosciences Co.

Shanghai Junshi Biosciences Co. is an Asset Manager based in Shanghai, China.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Shanghai, China
- **Region:** Asia
- **Address:** Shanghai, China
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** junshipharma.com
- **LinkedIn:** https://www.linkedin.com/company/junshi-biosciences

## Regulatory record

- **Reports private funds:** No

## About

Shanghai Junshi Biosciences, founded in 2012, is a Chinese biotechnology company led by chairman Feng Li and general manager Jun Du. The firm focuses on research, development, and commercialization of monoclonal antibodies and other biologic drugs, with a pipeline spanning oncology, autoimmune, and infectious disease indications. The company's core strategy centers on discovering and developing first-in-class and best-in-class biologics. Key assets include toripalimab, a PD-1 inhibitor approved in China for multiple cancers including melanoma and nasopharyngeal carcinoma, and a pipeline of candidates targeting immuno-oncology and inflammation. The firm also engages in partnerships with global biotech companies for co-development and licensing. Shanghai Junshi Biosciences employs over 1,000 people across its Shanghai headquarters and research facilities. The company went public on the Hong Kong Stock Exchange in 2018 and on the Shanghai STAR Market in 2020. Recent activity includes ongoing clinical trials and regulatory filings for toripalimab in the US and Europe (per SEC filings, 2023). The firm's structural differentiator is its position as a leading Chinese biotech with a globally validated PD-1 asset, navigating both domestic regulatory pathways and international expansion. Unlike many Chinese biotechs that rely solely on local development, Junshi partnered with Coherus BioSciences for US commercialization and seeks FDA approvals.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare Services

## People

- Feng Li — Chairman
- Jun Du — General Manager

## Questions

### Who leads investment decisions at Shanghai Junshi Biosciences?

Research and development strategy is directed by chairman Feng Li and general manager Jun Du. The company's scientific advisory board includes leading oncologists and immunologists (per firm's public filings).

### What is Shanghai Junshi Biosciences' core pipeline?

The company's lead product is toripalimab, a PD-1 inhibitor approved in China for multiple cancers. The pipeline also includes candidates targeting BTLA, TGF-beta, and other immuno-oncology targets, with programs in autoimmune diseases (per firm's annual report, 2022).

### How does Shanghai Junshi Biosciences commercialize its drugs?

The firm markets toripalimab directly in China through its own sales force. For ex-China markets, it partnered with Coherus BioSciences for North America and has licensing agreements in other regions (per SEC filings, 2023).

### What regulatory milestones has Shanghai Junshi Biosciences achieved?

Toripalimab received FDA approval for nasopharyngeal carcinoma in December 2023, making it the first Chinese-developed PD-1 inhibitor to gain US approval. It also holds approvals in China for melanoma and other indications (per FDA and NMPA announcements).

## Related profiles

- [Scoular](https://altss.com/profile/scoular)
- [International Refugee Assistance Project](https://altss.com/profile/international-refugee-assistance-project)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/shanghai-junshi-biosciences-co

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology